Given the critical role of the estrogen receptor signaling pathway in ovarian cancer development, a novel estrogen-targeted polyethylene glycol liposome (ES-SSL-OXA/PTX) encapsulating oxaliplatin and paclitaxel was developed to target the highly expressed ERs on the surface of SKOV-3 cells. Here, ESR1 is linked to ovarian cancer.